FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890767889> ?p ?o ?g. }

• W2890767889 endingPage "e0201005" @default.
• W2890767889 startingPage "e0201005" @default.
• W2890767889 abstract "Introduction The EXIST-2 (NCT00790400) study demonstrated the superiority of everolimus over placebo for the treatment of renal angiomyolipomas associated with tuberous sclerosis complex (TSC) or sporadic lymphangioleiomyomatosis (LAM). This post hoc analysis of EXIST-2 study aimed to assess angiomyolipoma tumor behavior among patients who submitted to continued radiographic examination following discontinuation of everolimus in the noninterventional follow-up phase. Methods For patients who discontinued everolimus at the completion of extension phase for reasons other than angiomyolipoma progression, a single CT/MRI scan of the kidney was collected after 1 year of treatment discontinuation. Changes from baseline and from the time of everolimus discontinuation in the sum of volumes of target angiomyolipoma lesions were assessed in the non-interventional follow-up phase (data cutoff date, November 6, 2015). Results Of the 112 patients who received ≥1 dose of everolimus and discontinued treatment by the end of extension phase, 34 (30.4%) were eligible for participation in the non-interventional follow-up phase. Sixteen of 34 patients were evaluable for angiomyolipoma tumor behavior as they had at least one valid efficacy assessment (i.e. kidney CT/MRI scan) after everolimus discontinuation. During the non-interventional follow-up phase, compared with baseline, two patients (12.5%) experienced angiomyolipoma progression (angiomyolipoma-related bleeding [n = 1], increased kidney volume [n = 1]). Five patients out of 16 (31.3%) experienced angiomyolipoma progression when compared with the angiomyolipoma tumor assessment at everolimus discontinuation. The median (range) percentage change in angiomyolipoma tumor volume (cm3) from baseline was −70.56 (−88.30; −49.64) at time of everolimus discontinuation (n = 11), and −50.55 (−79.40; −23.16) at week 48 (n = 7) after discontinuation of everolimus. One patient death was reported due to angiomyolipoma hemorrhage. Conclusions Angiomyolipoma lesions displayed an increase in volume following discontinuation of everolimus in patients with renal angiomyolipoma or sporadic LAM associated with TSC, but there was no evidence of rapid regrowth. Trial registration ClinicalTrials.gov NCT00790400" @default.
• W2890767889 created "2018-09-27" @default.
• W2890767889 creator A5003003819 @default.
• W2890767889 creator A5016958141 @default.
• W2890767889 creator A5043021976 @default.
• W2890767889 creator A5053002960 @default.
• W2890767889 creator A5056853441 @default.
• W2890767889 creator A5060425510 @default.
• W2890767889 creator A5070193666 @default.
• W2890767889 creator A5074767492 @default.
• W2890767889 creator A5075653724 @default.
• W2890767889 creator A5079238859 @default.
• W2890767889 creator A5088384086 @default.
• W2890767889 creator A5090299971 @default.
• W2890767889 date "2018-09-07" @default.
• W2890767889 modified "2023-10-06" @default.
• W2890767889 title "Angiomyolipoma rebound tumor growth after discontinuation of everolimus in patients with tuberous sclerosis complex or sporadic lymphangioleiomyomatosis" @default.
• W2890767889 cites W128188259 @default.
• W2890767889 cites W1797969281 @default.
• W2890767889 cites W1972329273 @default.
• W2890767889 cites W1980066502 @default.
• W2890767889 cites W2035079060 @default.
• W2890767889 cites W2035495486 @default.
• W2890767889 cites W2040065030 @default.
• W2890767889 cites W2050790870 @default.
• W2890767889 cites W2064165983 @default.
• W2890767889 cites W2126467306 @default.
• W2890767889 cites W2134749898 @default.
• W2890767889 cites W2156648692 @default.
• W2890767889 cites W2259186924 @default.
• W2890767889 cites W2285098929 @default.
• W2890767889 cites W2315424178 @default.
• W2890767889 cites W2328413810 @default.
• W2890767889 cites W2511735744 @default.
• W2890767889 cites W2743244669 @default.
• W2890767889 doi "https://doi.org/10.1371/journal.pone.0201005" @default.
• W2890767889 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6128468" @default.
• W2890767889 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30192751" @default.
• W2890767889 hasPublicationYear "2018" @default.
• W2890767889 type Work @default.
• W2890767889 sameAs 2890767889 @default.
• W2890767889 citedByCount "22" @default.
• W2890767889 countsByYear W28907678892019 @default.
• W2890767889 countsByYear W28907678892020 @default.
• W2890767889 countsByYear W28907678892021 @default.
• W2890767889 countsByYear W28907678892022 @default.
• W2890767889 countsByYear W28907678892023 @default.
• W2890767889 crossrefType "journal-article" @default.
• W2890767889 hasAuthorship W2890767889A5003003819 @default.
• W2890767889 hasAuthorship W2890767889A5016958141 @default.
• W2890767889 hasAuthorship W2890767889A5043021976 @default.
• W2890767889 hasAuthorship W2890767889A5053002960 @default.
• W2890767889 hasAuthorship W2890767889A5056853441 @default.
• W2890767889 hasAuthorship W2890767889A5060425510 @default.
• W2890767889 hasAuthorship W2890767889A5070193666 @default.
• W2890767889 hasAuthorship W2890767889A5074767492 @default.
• W2890767889 hasAuthorship W2890767889A5075653724 @default.
• W2890767889 hasAuthorship W2890767889A5079238859 @default.
• W2890767889 hasAuthorship W2890767889A5088384086 @default.
• W2890767889 hasAuthorship W2890767889A5090299971 @default.
• W2890767889 hasBestOaLocation W28907678891 @default.
• W2890767889 hasConcept C126322002 @default.
• W2890767889 hasConcept C126838900 @default.
• W2890767889 hasConcept C126894567 @default.
• W2890767889 hasConcept C2778715236 @default.
• W2890767889 hasConcept C2778980267 @default.
• W2890767889 hasConcept C2779052135 @default.
• W2890767889 hasConcept C2779699572 @default.
• W2890767889 hasConcept C2779997425 @default.
• W2890767889 hasConcept C2780091579 @default.
• W2890767889 hasConcept C71924100 @default.
• W2890767889 hasConceptScore W2890767889C126322002 @default.
• W2890767889 hasConceptScore W2890767889C126838900 @default.
• W2890767889 hasConceptScore W2890767889C126894567 @default.
• W2890767889 hasConceptScore W2890767889C2778715236 @default.
• W2890767889 hasConceptScore W2890767889C2778980267 @default.
• W2890767889 hasConceptScore W2890767889C2779052135 @default.
• W2890767889 hasConceptScore W2890767889C2779699572 @default.
• W2890767889 hasConceptScore W2890767889C2779997425 @default.
• W2890767889 hasConceptScore W2890767889C2780091579 @default.
• W2890767889 hasConceptScore W2890767889C71924100 @default.
• W2890767889 hasFunder F4320310388 @default.
• W2890767889 hasIssue "9" @default.
• W2890767889 hasLocation W28907678891 @default.
• W2890767889 hasLocation W28907678892 @default.
• W2890767889 hasLocation W28907678893 @default.
• W2890767889 hasLocation W28907678894 @default.
• W2890767889 hasLocation W28907678895 @default.
• W2890767889 hasOpenAccess W2890767889 @default.
• W2890767889 hasPrimaryLocation W28907678891 @default.
• W2890767889 hasRelatedWork W1970658103 @default.
• W2890767889 hasRelatedWork W2070404486 @default.
• W2890767889 hasRelatedWork W2080708628 @default.
• W2890767889 hasRelatedWork W2134749898 @default.
• W2890767889 hasRelatedWork W2177005046 @default.
• W2890767889 hasRelatedWork W2328413810 @default.
• W2890767889 hasRelatedWork W2335402523 @default.
• W2890767889 hasRelatedWork W2560674755 @default.

• next